Anti-Arthritic Activity of Bartogenic Acid Isolated from Fruits of Barringtonia racemosa Roxb. (Lecythidaceae) by Patil, Kalpesh Ramdas et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2011, Article ID 785245, 7 pages
doi:10.1093/ecam/nep148
Research Article
Anti-Arthritic Activity of Bartogenic AcidIsolated from Fruitsof
Barringtoniaracemosa Roxb. (Lecythidaceae)
Kalpesh Ramdas Patil,1 Chandragouda Raosaheb Patil,1 Ramchandra Baburao Jadhav,1
VallabhKrishnalalMahajan,1PrabhakarRaosahebPatil,2andPradeepSampatraoGaikwad1
1Department of Pharmacology, R.C. Patel Institute of Pharmaceutical Education and Research, Karvand Naka,
Shirpur, Maharashtra, India
2Navodaya Medical College, Raichur, Karnataka, India
Correspondence should be addressed to Kalpesh Ramdas Patil, kalpeshpharma20@gmail.com
Received 27 April 2009; Accepted 30 August 2009
Copyright © 2011 Kalpesh Ramdas Patil et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The fruits of Barringtonia racemosa are prescribed in the ayurvedic literature for the treatment of pain, inﬂammation and
rheumaticconditions. Inpresentinvestigation, activity guided isolation of bartogenic acid (BA)and its evaluation in the Complete
Freund’s Adjuvant (CFA)-induced arthritis in rats is reported. Among the various extracts and fractions investigated preliminarily
for carrageenan-induced acute inﬂammation in rats, the ethyl acetate fraction displayed potent anti-inﬂammatory activity. Large-
scale isolation and characterization using chromatography and spectral study conﬁrmed that the constituent responsible for the
observed pharmacological eﬀects was BA. Subsequently the BA was evaluated for eﬀectiveness against CFA-induced arthritis in
rats. The results indicate that at doses of 2, 5, and 10mgkg−1 day−1, p.o., BA protects rats against the primary and secondary
arthritic lesions, body weight changes and haematological perturbations induced by CFA. The serum markers of inﬂammation
and arthritis, such as C-reactive protein and rheumatoid factor, were also reduced in the BA-treated arthritic rats. The overall
severityof arthritisas determinedbyradiological analysis andpain scores indicated that BA exerts apotent protective eﬀectagainst
adjuvant-induced arthritis in rats. In conclusion, the present study validates the ethnomedicinal use of fruits of B. racemosa in the
treatment of pain and inﬂammatory conditions. It further establishes the potent anti-arthritic eﬀects of BA. However, additional
clinical investigations are needed to prove the eﬃcacy of BA in the treatment of various immuno-inﬂammatory disorders.
1.Introduction
The current treatment of rheumatoid arthritis is intended
to minimize the associated pain and inﬂammation using
non-steroidal anti-inﬂammatory drugs (NSAIDs) as well as
to decelerate the progress of the disease by using disease-
modifyinganti-rheumaticdrugs(DMARDs).DMARDssup-
press the immunological processes involved in the progres-
sion of rheumatoid arthritis. Drugs that have the eﬀects
of both DMARDs and NSAIDs may be more eﬀective
in the treatment of rheumatoid arthritis, but there is a
scarcity of such drugs acting through multiple mechanisms.
Hence, the treatment of rheumatoid arthritis involves the
combined use of NSAIDs and DMARDs [1]. Due to chronic
nature of rheumatoid arthritis, advanced age of the patients
and adverse reactions of the NSAIDs and DMARDs, the
arthritic patients tend to search for alternative treatments
that are eﬀective and less toxic and reduce the pill burden.
Hence, they commonly prefer complementary and alterna-
tive medicines [2].
In Indian traditional medicines, ayurvedic literature
describes potions containing parts of certain plants for
treating painful and inﬂammatory conditions like arthritis.
Barringtonia racemosa Roxb. (Lecythidaceae) is one such
plant [3, 4]. The extracts prepared from diﬀerent parts of
this plant have been reported to have various biological
activities such as anti-tumor, anti-nociceptive, α-glucosidase
inhibitory, anti-bacterial and anti-fungal activities [5–9].
Recently an extract of the leaves of B. racemosa has been
reported to possess anti-inﬂammatory and anti-oxidant
activity [10]. The observed activities have been correlated
with the lycopene present in B. racemosa leaves.
Several diterpenoids and triterpenoids have also been
isolated from various parts of B. racemosa and it has been2 Evidence-Based Complementary and Alternative Medicine
HO
HOOC
HO
HO
COOH
Figure 1: Chemical structure of BA (2α,3β,19β-trihydroxyolean-
12-en-23-28-dioic acid).
proposed that some of these are implicated in the biological
activities of the plant. The ethnomedicinal use of the fruits
of B. racemosa in arthritic disorders, however, has not
been systematically investigated so far. Furthermore, the
phytochemical moiety responsible for these eﬀects is not
yet known. Therefore, the present study was designed to
determine the anti-arthritic activity of bartogenic acid (BA),
a pentacyclic triterpenoid isolated from the fruits of B.
racemosa,intheCompleteFreund’sAdjuvant(CFA)-induced
arthritis model in rats.
2. Methods
2.1. Plant Material and Chemicals. Fruits of B. racemosa
were purchased from the local market. Dr P.S.N. Rao of
the Botanical Survey of India, Pune, India, authenticated
a specimen (voucher no 74843). A sample of an authentic
marker of BA was generously provided by Dr Mangala
Gowri, Senior Scientist, Indian Institute of Chemical Tech-
nology (IICT), Hyderabad, India, as a gift. A diclofenac
sodium (DCS) sample was received from Cipla Ltd, Goa,
India, as a gift. CFA was purchased from Sigma Aldrich,
USA. C-reactive protein (CRP) and Rhelax rheumatoid
factor (RF) kits were purchased from Agappe Diagnostics
Pvt. Ltd, Kerala, India, and Tulip Diagnostics Pvt. Ltd.,
Goa, India, respectively. Anesthetic ether was obtained from
Loba Chemicals, Mumbai. The other chemicals and solvents
used in the extraction, fractionation and chromatographic
separations were of analytical grade.
2.2.Extraction,IsolationandCharacterizationofBA. Hexane,
ethanol and methanol extracts were obtained by cold
maceration. The methanol extract displayed the most potent
anti-inﬂammatory activity in the carrageenan-induced paw
inﬂammation model in rats. Hence this extract was further
fractionatedinton-butanolandethylacetatefractions.When
compared with the same model of acute inﬂammation,
the ethyl acetate extract had a more potent eﬀect. Hence
it was used for further fractionation on a silica gel chro-
matography column, according to the procedure described
by Mangala et al. [9]. The pure compound, obtained from
large-scale extraction and isolation, was characterized by
comparing it with the authentic marker as well as by
comparing its FT-IR, proton NMR and LC-MS spectral data
with those in the literature [9]. The chromatographic and
spectral data are consistent with those of a previous study
[9], which conﬁrms that the isolated compound was BA
(Figure 1).
2.3. Animals and Experimental Design. Wistar rats of either
sex (100–150g weight) were used. The animals were main-
tained in plastic cages at 22 ± 2◦C with free access to pellet
food and water. The experimental protocols were approved
by the Institutional Animal Ethical Committee constituted
as per the rules of the Committee for the Purpose of
Control and Supervision of Experiments on Animals, India
(CPCSEA), laid down by the Government of India (Regd.
No. 651/02/C/CPCSEA).
2.4. CFA-Induced Arthritis in Rats. Each treatment group
contained six Wistar rats. The rats were randomly divided
into ﬁve groups: CFA control, BA (2mgkg−1 day−1, p.o.), BA
(5mgkg−1 day−1,p.o.),BA(10mgkg−1 day−1,p.o.)andDCS
(5mgkg−1 day−1, p.o.). Arthritis was induced by injection
of CFA according to a method described by Kumar et al.
[11]. In brief, on day 0, 100μL of CFA containing heat-killed
and dried Mycobacterium tuberculosis (strain H37Ra, ATCC-
25177) was injected into the paw of the right hind limb of
each rat.
2.5. Evaluation of the Severity of Arthritis. The primary and
secondary lesions, that is, paw volumes of injected and
non-injected paws, were measured using a digital plethys-
mometer (UGO Basile 7140, Italy), after which adjuvant
was administered. The lesions were measured again on the
7th, 14th, and 21st days after injection of the adjuvant [12,
13]. During the experimental period, the body weight was
measuredusingadigitalweighingbalanceevery3rddayafter
adjuvant injection. The severity of arthritis was recorded by
a blinded observer using the visual arthritis scoring systems
described by Kumar et al. and Laird et al. [11, 14]. The
arthritis score ranged from 0 to 4; where 0 indicates the
least but deﬁnite swelling and 4 represents the maximum
swelling. This scoring system involves observations of all
four paws and giving a separate score for each limb. Scores
were assigned for evaluation of the pain associated with the
arthritis as shown in Table 1.
Haematological parameters were evaluated using routine
laboratory methods. The level of serum CRP and RF
was determined using commercial kits according to the
manufacturers’ instructions.
2.6. Radiological Analysis. On day 21, animals were anes-
thetized with anesthetic ether. Radiographs of the adjuvant-
injected hind paws were taken with a X-ray instrument
(GE-525 DX, USA) Fuji computerized radiographic systems
(Japan). The ﬁlm focus distance was 60 inches and the
machine was operated at 43kV peak, 2mA. The X-ray image
of the adjuvant-injected limb of each rat was evaluated
for radiographic changes. As reported previously [14–16]Evidence-Based Complementary and Alternative Medicine 3
Table 1: Scoring system for evaluation of the pain associated with adjuvant induced arthritis.
Score Flexion pain test score Mobility score Stance score
0 No squeaking and no leg withdrawal Normal —
1 Either squeaking or leg withdrawal Limping Paw lifted continuously
2 Both squeaking and leg withdrawal Walking with diﬃculty Paw touching but with no weight bearing
3 — Walking without touching the injected paw Some weight bearing on the paw
4— Normal
Table 2: Primary and secondary arthritic lesions at 21st day in CFA-induced arthritis in rats.
Treatment Primary lesions (% rise in injected paw volume) Secondary lesions (% rise in non-injected paw volume)
CFA control 146 ± 4.4 19 ± 0.67
Diclofenac (5mgkg−1 day−1, p.o.) 83 ± 4.4∗∗ 13 ± 0.63∗∗
BA (2mgkg−1 day−1, p.o.) 113 ± 7.6∗∗ 15 ± 0.65∗∗
BA (5mgkg−1 day−1, p.o.) 109 ± 3.3∗∗ 12 ± 0.53∗∗
BA (10mgkg−1 day−1, p.o.) 91 ± 2.7∗∗ 11 ± 0.57∗∗
Data represented in mean ± SEM (n = 6).
∗∗P < .01, compared with control group.
the radiological alterations were arbitrarily graded between
0 and 4 according to the severity of the swelling of the
soft tissue around the joints of the hind paws, periarticular
bone resorption, periarticular bone erosion and narrowing
of the joint space. At the end of the study, the animals were
sacriﬁced with an overdose of anesthetic ether. The thymus
and spleen of all the animals were removed and weighed
[17, 18].
2.7.StatisticalAnalysis. Theresultsareexpressedasthemean
± SEM for the parametric data sets and as the median
(minimum, maximum) for the non-parametric data sets.
The signiﬁcance of the diﬀerence was evaluated by one-way
ANOVA followed by Dunnett’s multiple comparisons test
for normal data and by the Kruskall-Wallis test followed by
Dunn’s multiple comparison test for the scored data. Data
were considered statistically signiﬁcant if P < .05.
3. Results
3.1. BA Reduced Primary and Secondary Arthritic Lesions in
Rats. Observations such as the paw volumes, body weight
and arthritis scores were recorded on the 7th, 14th, and
21st days after adjuvant injection. The CFA-induced arthritis
control group showed signs of arthritis development, as seen
by the increase in the paw volumes in both CFA-injected
and CFA-non-injected paws, which indicates primary and
secondary arthritic lesions. Other indications, such as a
decreased body weight and alterations in the arthritis scores,
also showed induction of arthritis in the CFA-treated control
group rats.
The assessment made on the 21st day showed that
the DCS and BA treatments had signiﬁcantly reduced the
adjuvant-induced primary and secondary lesions in the
respective treatment groups as compared with the CFA
control group (Table 2). It is noteworthy that the reduction
in the secondary lesions was comparable in the DCS-treated
and BA 5 mg/kg treated groups.
3.2. BA Improved the Body Weight Gain and Decreased Spleen
and Thymus Weights in Arthritic Rats. The average gain in
the body weight on day 21 as compared with the initial body
weight in each treatment group has been given in Table 3.
The rats in the CFA control group gained less body weight as
compared with the BA- and DCS-treated groups. This eﬀect
on the body weight was clearly evident even at the lowest
tested dose of 2mg/kg of BA.
The weights of the spleen and thymus recorded after
sacriﬁcingtheratsonday21weresigniﬁcantlyreducedinthe
BA-treated group. The 10 mg/kg dose of BA caused a greater
reduction in the thymus weight than did the DCS (5 mg/kg)
treatment.
3.3. Haematological Alterations in CFA Rats were Normalized
after Treatment with BA. The CFA-induced haematological
perturbations, such as an increase in the WBC count, a
decreased RBC count, a decreased hemoglobin (Hb) count
and an increased erythrocyte sedimentation rate were also
favorably altered by BA treatment (Table 4).
3.4. The Levels of CRP and RF were Suppressed by BA
Treatment. The serum CRP and RF are markers of systemic
inﬂammation and antibody production against the injected
adjuvant. High levels of serum CRP (8.8mg/dL) and serum
RF (73IU/mL) were observed in the CFA control group rats.
TheBAandDCStreatmentsreducedtheincreaseinthelevels
of both CRP and RF in the serum (Table 4). The eﬀects of
BA were dose-dependent, and the 10mg/kg dose of BA and
5mg/kg dose ofDCShadequipotent eﬀectsin decreasingthe
serum RF levels.
3.5. Pain Scores were Normalized in the BA-Treated Groups.
BA treatment favorably aﬀected the pain scores, indicating a4 Evidence-Based Complementary and Alternative Medicine
Table 3: Body and organ weights changes in CFA-induced arthritis in rats.
Group Body weight gain (g) Thymus weight (g) Spleen weight (g)
CFA control 24 ± 1.1 0.19 ± 0.022 1.1 ± 0.12
Diclofenac 41 ± 1.7∗∗ 0.1 ± 0.0074∗∗ 0.95 ± 0.042
BA (2mgkg−1 day−1, p.o.) 37 ± 1.6∗∗ 0.12 ± 0.011∗∗ 0.96 ± 0.085
BA (5mgkg−1 day−1, p.o) 36 ± 0.96∗∗ 0.12 ± 0.013∗∗ 0.84 ± 0.048∗
BA (10mgkg−1 day−1 p.o) 39 ± 1.1∗∗ 0.085 ± 0.009∗∗ 0.74 ± 0.085∗∗
Data represented in mean ± SEM (n = 6).
∗P < .05, ∗∗P < .01, compared with control group.
Table 4: Alterations in hematological parameters, CRP and RF in CFA-induced arthritis in rats.
Group RBC (×106/mm3)W B C ( ×103/mm3) ESR (mm/h) Hb (mg%) CRP (mg/dL) RF (IU/mL)
CFA control 7.3 ± 0.2 13 ± 0.4 14 ± 0.3 12 ± 0.4 8.8 ± 0.8 73 ± 6.7
Diclofenac (5mgkg−1 day−1, p.o.) 9.2 ± 0.2∗∗ 5.5 ± 0.2∗∗ 10 ± 0.2∗∗ 15 ± 0.3∗∗ 1.8 ± 0.3∗∗ 23 ± 3.3∗∗
BA (2mgkg−1 day−1, p.o.) 8 ± 0.3 7.5 ± 0.3∗∗ 12 ± 0.2∗∗ 13 ± 0.5 4.4 ± 0.4∗∗ 37 ± 3.3∗∗
BA (5mgkg−1 day−1, p.o.) 9 ± 0.2∗∗ 7.2 ± 0.3∗∗ 13 ± 0.3 15 ± 0.4∗∗ 2.2 ± 0.2∗∗ 33 ± 4.2∗∗
BA (10mgkg−1 day−1, p.o.) 9.8 ± 0.2∗∗ 5.6 ± 0.2∗∗ 11 ± 0.3∗∗ 16 ± 0.3∗∗ 1.4 ± 0.2∗∗ 23 ± 3.3∗∗
Data represented in mean ± SEM (n = 6).
∗∗P < .01, compared with control group.
signiﬁcant decrease in the pain associated with the adjuvant-
induced arthritis (Table 5). All the estimated pain scores,
including the ﬂexion pain test score, mobility score and
stancescore weresigniﬁcantly altered in DCS-treated and BA
(10mg/kg)-treated rats. The reduction in the mobility score
was greater in the BA (10mg/kg)-treated group as compared
with the DCS-treated group.
3.6. BA Protected the Rats from CFA-Induced Radiographic
Changes. Figure 2(a) shows representative photographs of
the tarsotibial joint swelling of the right hind paws of rats
from diﬀerent groups on the 14th day after CFA injection.
Figure 2(b) shows X-ray radiographs of the same paws
taken on the 21st day. It is clearly observed in the X-rays
that the soft tissue swelling around the joints, periarticular
bone resorption, periarticular bony erosions and joint space
narrowing in the rats treated with BA have been protected
from the CFA-induced arthritis-related joint changes.
4. Discussion
CFA-induced arthritis is the most widely used chronic
test model in which the clinical and pathological changes
are comparable with those seen in human rheumatoid
arthritis [19, 20]. Chronic inﬂammation in the CFA model
is manifested as a progressive increase in the volume of the
injected paw. It is noteworthy that the inhibitory eﬀect of BA
(10mgkg−1 day−1) on the volume of the injected paw was
comparable with that of DCS (5mgkg−1 day−1)( Table 2).
CFA-inducedpolyarthritisisassociatedwithanimmune-
mediated inﬂammatory reaction and the rat is unique in
developing polyarthritis afterCFAtreatment[16].Theinitial
reaction of edema and soft-tissue thickening at the depot
site in this model is caused by the irritant eﬀect of the
adjuvant, whereas the late-phase arthritis and ﬂare in the
injected foot are presumed to be immunologic events [21].
The appearance of secondary lesions, that is, non-injected
paw swelling is a manifestation of cell-mediated immunity.
Thesuppressionofsuchsecondarylesionsbyadrugshowsits
immunosuppressive activity [12, 13]. BA eﬀectively reduced
the secondary lesions in arthritic rats (Table 2). Moreover,
thiseﬀectofBAwasmorepotentthanthatofdiclofenac.This
reveals potent suppression by BA of cell-mediated immunity
in arthritic rats. Similarly, it reduced the arthritic score and
secondary paw swelling. A selective reduction in the arthritis
score distinguishes the immunosuppressive eﬀects of a drug
from its anti-inﬂammatory eﬀects [15]. The reduction of the
arthritis score by BA as observed in our study indicates a
possible immunosuppressant eﬀect(Table 5).Thesigniﬁcant
reduction of the thymus weight in the BA-treated groups
further supports this observation.
CFA-induced arthritis in rats is associated with an
increase in the plasma levels of RF and CRP [22, 23]. The
treatment with BA signiﬁcantly reduced the levels of these
biomarkersofinﬂammationandautoimmunestimulationin
the treated rats (Table 4).
Other miscellaneous information related to the pathol-
ogy of arthritis that has been obtained during this study
includes radiographic examination of the paws, haematolog-
ical parameters, body weight changes, organ weight changes
and paw withdrawal latency. The radiographic observations
of the rats show that the treatment with BA and DCS
inhibited the arthritis-associated joint changes (Figure 2). In
the DCS- and BA-treated groups there was restoration of the
body weights of the rats. A report by Patil et al.[24] suggests
that the decrease in the body weight during inﬂammation is
duetodeﬁcientabsorptionofnutrientsthroughtheintestine
andthattreatmentwithanti-inﬂammatorydrugsnormalizes
the process of absorption. The evident restoration of the
body weight of rats in the BA- and DCS-treated groups mayEvidence-Based Complementary and Alternative Medicine 5
Table 5: Changes in various pain test scores in CFA-induced arthritis in rat.
Group Arthritis score Flexion pain test score Mobility score Stance score
CFA control 12 (10, 13) 3 (2, 3) 3 (2, 3) 1 (1, 2)
Diclofenac (5mgkg−1 day−1, p.o.) 4.5 (3, 6)∗∗ 1 (1, 2)∗∗ 2 (1, 2)∗ 3 (2, 3)∗∗
BA (2mgkg−1 day−1, p.o.) 10 (9, 11) 2 (1, 3) 2 (2, 3) 2 (1, 3)
BA (5mgkg−1 day−1, p.o) 9 (6, 11) 2 (1, 2) 2 (1, 3) 2 (2, 3)
BA (10mgkg−1 day−1, p.o) 6 (4, 8)∗∗ 1.5 (1, 2)∗ 1.5 (1, 2)∗∗ 3 (2, 3)∗∗
Data represented in median (minimum, maximum), n = 6.
∗P < .05, ∗∗P < .01, compared with control group.
CFA control
Diclofenac 5mg/kg
Bartogenic acid 10mg/kg
(a) Photographs of the rat paws
CFA control
Diclofenac 5mg/kg
Bartogenic acid 10mg/kg
(b) Radiographs of the rat paws
Figure 2: Photographic and radiographic analysis of CFA-induced arthritis in rats. (a) Photograph of the right hind paw taken 14 days after
CFA injection and (b) Radiographic analysis of the same right hind paws at Day 21 after CFA injection.
involveimprovementofintestinalabsorptionofthenutrients
and a reduction in the distress caused by the severity of the
arthritis.
It has been reported that a moderate rise in the WBC
count occurs in arthritic conditions due to an IL-1B-
mediated rise in the respective colony-stimulating factors.
The present study reveals that BA and DCS treatments tend
to normalize the WBC count. In addition to this, other char-
acteristic haematological alterations such as the decreased
Hb count and increased erythrocyte sedimentation rate
[12] were also restored by the BA and DCS treatments
(Table 4). It is proposed that the reduction in the Hb count
during arthritis results from reduced erythropoietin levels,
a decreased response of the bone marrow erythropoietin6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Anti-arthritic activity of BA. Cross mark indicates inhibition of CFA induced pathological changes in rats by Bartogenic acid.
GM-CSF, granulocyte macrophage colony stimulating factor; ACP, acute phase proteins.
and premature destruction of red blood cells. Similarly, an
increase in the ESR is attributed to the accelerated formation
of endogenous proteins such as ﬁbrinogen and α/β globulin,
and such a rise in the ESR indicates an active but obscure
disease process [18]. Thus, the reduction in the ESR and
increase in the Hb count brought about by BA treatment
further support its anti-arthritic eﬀect.
The reduction in spleen weight and increase in thymus
weight are related to a stimulatory eﬀect on the immune
system [25]. The observed decrease in the spleen and thymus
weights in the BA-treated rats indicates alterations in the
cell populations in these organs, which are related to the
immune function. Dexamethasone produces a reduction in
spleen and thymus weights that can be attributed to its
anti-proliferative action. BA also displayed similar eﬀects
on these organs. Although these observations indicate an
immunosuppressant activity of BA, direct evidence needs to
be generated to conﬁrm the immunosuppressant eﬀect.
Arthritis is an inﬂammatory condition of the bone joints
that is associated with hyperalgesia and functional impair-
ment. The hyperalgesia associated with arthritis is mediated
through prostaglandins and other endogenous mediators
[26]. In the present study, the eﬀect of BA on arthritis-
induced hyperalgesia was evaluated by visually attributed
arthritic scores and the dorsal ﬂexion pain test. BA eﬀectively
increased the pain threshold and reduced the ﬂexion pain
test score (Table 5). Furthermore, the mobility and stance
scores, which are commonly used to assess the functional
impairment in arthritis were determined. BA treatment
lowered the mobility score and improved the stance score,
indicating a reduction in pain (Table 5). Though actual
quantiﬁcation of the mediators of pain was not per-
formed in this study, it is proposed that BA signiﬁcantly
aﬀects the levels/eﬀects of such endogenous pain mediators
[11].
It is now recognized that single target- and single
molecule-based drug development has been less relevant in
many chronic diseases because these diseases involve mul-
tiple organ systems and interdependent etiological factors.
Even mainstream drug discovery is now deviating from such
asinglemoleculeandsingletargetapproachtocombinations
and multiple-target approaches [27]. The treatment of a
disease like arthritis is expected to address the alterations
in the multiple mediators and/or their eﬀects to derive
clinical beneﬁts. As evident from the results of the present
study, a plant-derived triterpenoid, BA appears to exert
beneﬁcial eﬀects on multiple pathological manifestations
of CFA-induced arthritis in rats (Figure 3). Therefore this
molecule may prove to be of clinical value if systematically
investigated further. In addition, the present study validatesEvidence-Based Complementary and Alternative Medicine 7
the ethnomedicinal use of fruits of B. racemosa in the
treatment of pain and inﬂammatory conditions.
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